caa a22 4500 475833600 CHVBK 20180406123847.0 cr unu---uuuuu 170329e20000601xx s 000 0 eng 10.1023/A:1007816300468 doi (NATIONALLICENCE)springer-10.1023/A:1007816300468 Efficacy of Two Lipid-Lowering Treatments on Quantitative Coronary Angiographic Endpoints [Elektronische Daten] [W.J. Mack, M. Xiang, A.M. Shircore, R.H. Selzer, H.N. Hodis, S.P. Azen] This study contrasts the sensitivity of four quantitative coronary angiography (QCA) measures (percent diameter stenosis [%S], minimum lumen diameter, average segment diameter, and percent involvement) in detecting 2-year treatment effects of two lipid-lowering therapies and reports on the longitudinal pattern after 4 years of treatment on the primary QCA trial endpoint (%S) for all, mild/moderate (<50%S), and severe lesions (≥50%S). Patient cohorts were followed up from two randomized, placebo-controlled clinical trials of lipid-lowering therapies—colestipol/niacin in the Cholesterol Lowering Atherosclerosis Study (CLAS) and lovastatin in the Monitored Atherosclerosis Regression Study (MARS). Identical QCA methodology was used. In CLAS, the largest 2-year treatment effect size (=0.60) was noted for %S. In MARS, equivalent 2-year effect sizes (=0.15) were noted for three QCA measures. The largest 2-year effect size in %S was found in CLAS for mild/moderate lesions (=0.55) and in MARS for severe lesions (=0.31). Treatment in CLAS led to regression of disease in the first 2 years; treatment in MARS slowed progression of disease in the first 2 years and led to regression of disease after 4 years. Colestipol/niacin reduced progression of mild/moderate and severe lesions over the first 2 years of therapy; lovastatin reduced the progression of severe lesions over the last 2 years of therapy. We conclude that reducing the progression of atherosclerosis is not a simple proposition; maximal therapy for reducing and stabilizing atherosclerosis most likely will result from the selection of agents targeted at specific lesions. Kluwer Academic Publishers, 2000 coronary angiography nationallicence clinical trial nationallicence quantitative coronary angiography nationallicence Mack W.J. Statistical Consultation and Research Center, Department of Preventive Medicine, and Atherosclerosis Research Unit, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA aut Xiang M. Statistical Consultation and Research Center, Department of Preventive Medicine, and Atherosclerosis Research Unit, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA aut Shircore A.M. Jet Propulsion Laboratory, Pasadena, California, USA aut Selzer R.H. Jet Propulsion Laboratory, Pasadena, California, USA aut Hodis H.N. Statistical Consultation and Research Center, Department of Preventive Medicine, and Atherosclerosis Research Unit, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA aut Azen S.P. Statistical Consultation and Research Center, Department of Preventive Medicine, and Atherosclerosis Research Unit, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/4(2000-06-01), 411-418 0920-3206 14:4<411 2000 14 10557 https://doi.org/10.1023/A:1007816300468 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007816300468 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mack W.J. Statistical Consultation and Research Center, Department of Preventive Medicine, and Atherosclerosis Research Unit, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA aut NATIONALLICENCE 700 1- Xiang M. Statistical Consultation and Research Center, Department of Preventive Medicine, and Atherosclerosis Research Unit, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA aut NATIONALLICENCE 700 1- Shircore A.M. Jet Propulsion Laboratory, Pasadena, California, USA aut NATIONALLICENCE 700 1- Selzer R.H. Jet Propulsion Laboratory, Pasadena, California, USA aut NATIONALLICENCE 700 1- Hodis H.N. Statistical Consultation and Research Center, Department of Preventive Medicine, and Atherosclerosis Research Unit, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA aut NATIONALLICENCE 700 1- Azen S.P. Statistical Consultation and Research Center, Department of Preventive Medicine, and Atherosclerosis Research Unit, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/4(2000-06-01), 411-418 0920-3206 14:4<411 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer